Can we safely discontinue first-line medication in MS patients with long-term absence of inflammation, without the return of inflammatory disease activity clinically and radiologically?
Is it possible to detect and predict (return of) inflammatory disease activity and disease progression with digital biomarkers using mobile applications such as MS sherpa?
Study group
(Amsterdam UMC) N= 130 patients.
Planning
Protocol approved by METC, recruitment ongoing.
APPS MS study
Goal
Develop and explore measuring methods using built-in sensors of conventional smartphones and wearables to quantify fatigue, disease activity and progression in a day-to-day setting in patients with MS.
Study group
N= 125, 100 persons with MS, 25 healthy controls, collaboration with Amsterdam UMC, last patient visited in February 2021.
Planning
In data analysis phase, scientific publications are in preparation.
The aim of this study is to assess the validity, sensitivity and ease of use of new mobile self-monitoring tools for people with Relapsing-Remitting Multiple Sclerosis.
In this study, the primary aim is to evaluate the effectiveness, in terms of self-efficacy control and quality of life, and the cost-effectiveness of self-monitoring based management of MS through the use of the MS sherpa app compared to care as usual without MS sherpa.
Study group
N= 225, 125 intervention group, 100 control group, collaboration with Amsterdam UMC, 3 STZ hospitals, MS4Research institute and the Radboud University.
